Phytoconstituents and biofunctional attributes of Adenophora triphylla: A review

Key findings from this study

• The review identifies that over 130 phytoconstituents have been characterized from A. triphylla tissues, primarily comprising triterpenoids, polyphenols, flavonoids, and phenylpropanoids.
• The authors report that both plant extracts and isolated compounds demonstrate diverse pharmacological activities including antioxidant, anti-cancer, anti-diabetic, anti-inflammatory, and hepatoprotective properties in preclinical models.
• The review identifies that root tissues account for the majority of documented pharmacological activities, suggesting differential bioactivity across plant morphology.

Overview

This review synthesizes current knowledge regarding Adenophora triphylla, a medicinal plant from the Campanulaceae family with traditional use in medicine and food applications. The review consolidates botanical characterization, traditional usage patterns, phytochemical composition, and documented pharmacological properties derived from preclinical investigations. The primary objective addresses a documented gap in comprehensive syntheses of this plant's bioactive constituents and their biological activities.

Methods and approach

The review examined phytochemical data and pharmacological studies documenting over 130 identified compounds from aerial and root tissues of A. triphylla. Documented compound classes include triterpenoids, polyphenols, flavonoids, and phenylpropanoids. Pharmacological activities were assessed across cell-based and animal-based experimental models, with emphasis on extract- and isolated compound-derived bioactivities.

Results

The phytochemical profile of A. triphylla comprises more than 130 characterized constituents distributed across aerial and root tissues, with root extracts representing the predominant source of documented pharmacological activity. Preclinical investigations report antioxidant, anti-obesity, anti-cancer, anti-diabetic, anti-inflammatory, lung-protective, hepatoprotective, osteogenesis-promoting, anti-angiogenic, anti-fungal, and anti-melanogenic activities. The evidence base derives substantially from cell-based and animal models, with limited clinical validation and minimal pharmacokinetic or safety data.

Implications

The extensive phytochemical diversity and multifaceted pharmacological profile documented in preclinical systems establish A. triphylla as a candidate for further therapeutic development. The concentration of bioactivity in root tissue suggests differential distribution of bioactive constituents across plant morphology and indicates that botanical sourcing practices warrant consideration for subsequent investigations. The current evidentiary foundation, predominantly derived from cellular and animal models, necessitates systematic clinical validation to establish efficacy and safety parameters in human populations.

Scope and limitations

This summary is based on the study abstract and available metadata. It does not include a full analysis of the complete paper, supplementary materials, or underlying datasets unless explicitly stated. Findings should be interpreted in the context of the original publication.